NDAINTRAVENOUSSOLUTION
Approved
Aug 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
3/8 — Basic
Drug data last refreshed 18h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OLINVYK (oliceridine) is an intravenous opioid analgesic approved by the FDA in August 2020 for moderate to severe acute pain management. It is a small-molecule mu-opioid receptor agonist designed for hospital and acute care settings where rapid, short-acting pain relief is needed. The drug represents an innovation in opioid therapy targeting postoperative and acute pain populations.
Peak5.8 years to LOE
Product is in peak commercial phase post-launch with approximately 4 years of market presence; team size and growth trajectory dependent on hospital adoption rates and formulary penetration in acute care.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Bunionectomy
Started May 2016
418 enrolled
Acute Pain
Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Abdominoplasty
Started May 2016
407 enrolled
Acute Pain
Career Relevance
OLINVYK roles are concentrated in acute care and hospital sales, requiring expertise in formulary management, healthcare provider relationships, and acute pain management. Career growth is moderate given the niche acute IV opioid market and approaching LOE timeline; professionals should prioritize maximizing adoption before patent expiration.
Brand Manager
Worked on OLINVYK at Trevena? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.